Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptorsP S Linsley, Robert Peach, JoAnne L. Greene et al.|Immunity|1994Cited by 971
Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive PropertiesChristian P. Larsen, Robert Peach, Dan Anderson et al.|American Journal of Transplantation|2005Cited by 708
Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1.Robert Peach, Peter S. Linsley, Jürgen Bajorath et al.|The Journal of Experimental Medicine|1994Cited by 246
Covalent Dimerization of CD28/CTLA-4 and Oligomerization of CD80/CD86 Regulate T Cell Costimulatory InteractionsJoAnne L. Greene, Peter S. Linsley, Gina Leytze et al.|Journal of Biological Chemistry|1996Cited by 238
CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritisJohn J. Reynolds, Charles D. Pusey, Frederick W.K. Tam et al.|Journal of Clinical Investigation|2000Cited by 176